KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $19.7 million.

  • AbCellera Biologics' Gains from Investment Securities fell 90.22% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.3 million, marking a year-over-year decrease of 123.61%. This contributed to the annual value of $19.7 million for FY2024, which is 43.96% up from last year.
  • AbCellera Biologics' Gains from Investment Securities amounted to $19.7 million in FY2024, which was up 43.96% from $13.7 million recorded in FY2023.
  • AbCellera Biologics' Gains from Investment Securities' 5-year high stood at $30.3 million during FY2021, with a 5-year trough of $13.7 million in FY2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $19.7 million (2024), whereas its average is $19.7 million.
  • In the last 5 years, AbCellera Biologics' Gains from Investment Securities surged by 10,021.13% in 2020 and then plummeted by 46.69% in 2023.
  • Over the past 5 years, AbCellera Biologics' Gains from Investment Securities (Yearly) stood at $19.2 million in 2020, then skyrocketed by 57.55% to $30.3 million in 2021, then declined by 15.32% to $25.7 million in 2022, then plummeted by 46.69% to $13.7 million in 2023, then soared by 43.96% to $19.7 million in 2024.